Adenocarcinoma
1.

Introduction
The incidence rate of oesophageal adenocarcinoma is, for reasons not fully understood, increasing rapidly in western countries, particularly among white men. [1] [2] [3] [4] [5] The strong (6:1) male predominance is not explained by gender-related differences in known risk factors (reflux, obesity or smoking) or protective factors (fruit and vegetable consumption or Helicobacter pylori infection). 6 The gender-associated difference in incidence rates may be attributable to an as yet unidentified protective factor in women, such as female sex hormones. Few studies have investigated the association of exogenous hormones and risk of oesophageal adenocarcinoma. A cohort study in Sweden 7 found no association between the incidence of oesophageal adenocarcinoma among men who had previously received anti-androgenic treatment (i.e. oestrogen) for prostate cancer. However, research has suggested a decreased incidence of oesophageal adenocarcinoma among men with a history of prostate cancer. 8, 9 A study conducted among women in the United Kingdom (UK) found no protective effect of hormone replacement therapy in the aetiology of oesophageal adenocarcinoma. 10 A population-based study which investigated the relation between body mass index (BMI) and reflux, two major risk factors for oesophageal adenocarcinoma, found stronger positive associations among pre-menopausal than post-menopausal women. 11 However, the use of hormone replacement therapy increased the strength of the association between BMI and reflux among post-menopausal women. Together, these data suggest that some of the key risk factors for oesophageal adenocarcinoma are modified by female hormones. A potential role of oral contraceptives has never been investigated. Regarding endogenous reproductive factors, pregnancy may be associated with oesophageal adenocarcinoma risk. Gastrooesophageal reflux, 12 for example, is common during pregnancy. 13 Furthermore, an increased susceptibility to H.
pylori, a potential protective factor in oesophageal adenocarcinoma development, 14 during pregnancy has been documented. 15 A Swedish case-control study reported no evidence of an association of parity with oesophageal adenocarcinoma. 16 However, a dose-dependent association between duration of breastfeeding and risk of oesophageal adenocarcinoma has been reported in a case-control study from the UK. 17 The impact of endogenous reproductive factors on oesophageal carcinogenesis has otherwise not been examined.
The relatively low incidence of oesophageal adenocarcinoma among women has prohibited much research of reproductive factors in the aetiology of oesophageal adenocarcinoma. The few available studies have been hampered by low statistical power. We therefore pooled data on female participants from four large and independent case-control studies which investigated risk factors for oesophageal and gastric junction adenocarcinomas and present the largest population-based study to date aiming to investigate whether endogenous and exogenous reproductive and hormonal factors play a role in the aetiology of oesophageal and gastric junction adenocarcinoma.
2.
Patients and methods Population-based controls were frequency matched by age (within 5 years) and gender to oesophageal and gastric junction adenocarcinoma cases.
Selection of studies for analysis
The US Kaiser Permanente case-control study was nested within a cohort of Kaiser Permanente health plan members who underwent a health checkup and completed a questionnaire between 1964 and 1973. For each oesophageal and gastric junction adenocarcinoma case, eight controls, matched for age, gender and year of health checkup were selected from within the health plan. 20 To ensure a uniform outcome, in the Australian study, we excluded patients with adenocarcinomas at sites denoted as 'cardia', 'gastrooesophageal/cardia', 'unknown' and 'biopsy' (n = 10) as these were not included in all studies. In the United States (US) study, we excluded patients with adenocarcinomas at the gastric cardia and gastric body (n = 11).
Study variables
Information available on reproductive factors included menstrual factors (age at menarche and age when periods stopped), childbearing (number of pregnancies and number of children), breastfeeding (history and duration), use of hormone replacement therapy (ever or never) and use of oral contraceptives (ever or never). A pregnancy was defined as any pregnancy of at least 6 months duration, including still or live births, but not miscarriages. Not all of the variables were available for each study; studies have been included in the analysis for factors for which data were available. Data on potential confounding factors included age at diagnosis or interview (categorised into three groups,<50, 50-65, P65 years), tobacco smoking status (never or ever over lifetime), alcohol consumption (never or ever over lifetime), education (years of formal education), history of reflux (never or ever; assessed at 5 years before diagnosis for the Irish study, 10 years before diagnosis for the Australian, without latency period in the UK and US studies), BMI before diagnosis (1 year in Australian and US studies and 5 years in Irish) and at heaviest during their lifetime (UK study). Please see On-line Appendix A for details of questions from each study.
Statistical methods
A single file including comparable variables, coded in a uniform format, was compiled from the four datasets. In univariable analyses, v 2 tests were used to examine differences in variables between case and control groups. The statistical analyses were carried out using two approaches, both of which generated similar results, therefore only the results of the aggregated analysis are presented.
Aggregated analysis approach
In the combined dataset, the odds ratios (ORs) and associated 95% confidence intervals (CIs) associating reproductive and hormone factors and risk of oesophageal and gastric junction adenocarcinoma were estimated using multiple logistic regression. All ORs were adjusted for age and study. In a multivariable model, ORs were also adjusted for BMI (in three groups: <24, 24-28, P28), history of reflux (ever, never or unknown), years of education (<12 years or 12+years), alcohol drinking (ever or never) and tobacco smoking status (ever or never). These factors were included in models a priori due to their association with oesophageal and gastric junction adenocarcinoma risk. Forest plots were constructed to illustrate findings from logistic regression analyses in individual studies and the pooled analysis.
Meta-analysis approach (data not presented)
The analysis was carried out using two steps. 22 The ORs and associated 95% CIs associating reproductive and hormone factors and risk of oesophageal and gastric junction adenocarcinoma were estimated for each study using multiple logistic regression. Minimally adjusted ORs were adjusted for age. Multivariable ORs were further adjusted, as above, for BMI, history of reflux, years of education, alcohol and tobacco smoking status. The second step involved pooling the studyspecific ORs using a random effects model. 22 Heterogeneity between the results of different studies was examined by inspecting the forest plot of a meta-analysis for variation in effects. Tests for heterogeneity were considered in conjunction with graphical approaches to determine between-study differences.
All statistical tests were 2-sided. Analyses were carried out using STATA 9.0 (StataCorp, Texas, USA).
Ethics
Ethical approval was obtained from the local ethical boards where each study was carried out.
Results
Characteristics of the 218 oesophageal and gastric junction adenocarcinoma female cases and 862 female control subjects included are outlined in Table 1 . Compared to the control group, the case group had a higher prevalence of reflux and smoking and a higher BMI. Data on reproductive factors are presented in Table 2 . No associations were observed between menstruation variables, i.e. age at first period or age when periods ended and risk of oesophageal and gastric junction adenocarcinoma. Compared with women with three or more children, those with one or two children (OR = 1.20, 95% CI = 0.84-1.72) and no children (OR = 1.27, 95% CI = 0.77-2.10) had a possibly increased risk of oesophageal adenocarcinoma (p for trend = 0.048). The apparent protective effect for three or more children was not evident in the minimally adjusted model; a history of reflux was most responsible for this confounding. The suggested protective effect associated with parity remained after adjusting for breastfeeding in an analysis restricted to parous women (data not shown).
Compared with women who had children but did not breastfeed, a history of breastfeeding was associated with a statistically significantly reduced risk of oesophageal and gastric junction adenocarcinoma (OR = 0.58, 95% CI = 0.37-0.92). This association was dose-dependent (p for trend with increased duration of breastfeeding < 0.001), and women who breastfed for more than 12 months were at a 58% decreased risk of developing oesophageal and gastric junction adenocarcinoma (OR = 0.42, 95% CI = 0.23-0.77). Forest plots showing the association for occurrence and duration of breastfeeding with oesophageal and gastric junction adenocarcinoma are presented in Figs. 1a and 1b . As the UK study had previously reported an inverse association with breastfeeding 13 we also repeated our analysis excluding this study. The trend of a decreased risk of oesophageal and gastric junction adenocarcinoma associated with breastfeeding remained (ever breastfed compared with parous women who never breastfed: OR = 0.75, 95% CI = 0.43-1.33; breastfeeding duration: >0-6 months OR = 0.78, 95% CI = 0.40-1.52; 7-12 months: OR = 0.78, 95% CI = 0.38-1.60; >12 months: OR = 0.61, 95% CI = 0.30-1.23, p for trend = 0.017). We repeated our analyses comparing oesophageal adenocarcinoma cases only with controls. We observed similar findings for women with a history of breastfeeding (compared with parous women who never breastfed), OR = 0.42, 95% CI = 0.24-0.75. Women who breastfed for over 12 months had a 78% decreased risk of oesophageal adenocarcinoma (OR = 0.22, 95% CI = 0.10-0.52).
Ever users of hormone replacement therapy had a possibly decreased risk of oesophageal and gastric junction adenocarcinoma (OR = 0.75, 95% CI = 0.45-1.24), but this was not statistically significant. When we restricted this to oesophageal adenocarcinoma cases only, there was no evidence of a decreased risk (OR = 0.99, 95% CI = 0.49-2.01). Use of oral contraceptives was not associated with risk of oesophageal and gastric junction adenocarcinoma (Table 2 ).
Discussion
The current study indicated an inverse association between history of breastfeeding and risk of oesophageal and gastric junction adenocarcinoma. Other endogenous or exogenous reproductive factors did not appear to be strongly associated with risk of this tumour. Data regarding the impact of breastfeeding on gastrointestinal disease are sparse. Research on lactation has suggested a protective effect regarding cancers of the stomach, pancreas and gallbladder. [23] [24] [25] Reasons for a reduced risk of oesophageal and gastric junction adenocarcinoma among women with a history of breastfeeding remain to be elucidated. Investigators in the UK study speculated that the protective effect was attributable to higher weight gain after pregnancy in women who did not breastfeed. 17 However, there is no evidence in published literature that lactation prevents obesity 26, 27 Although we adjusted for BMI, we had no information on BMI during a woman's childbearing years, which may have been substantially different to their BMI shortly before oesophageal and gastric junction adenocarcinoma diagnosis. Such weight change may have been differential between cases and controls. A reduced risk of oesophageal and gastric junction adenocarcinoma associated with breastfeeding is biologically plausible and may be similar to that observed in 'hormonerelated' cancers (breast, endometrial and ovary [28] [29] [30] ). For example, a high frequency of oestrogen receptor (ER) expression, particularly ER beta, 31 has been reported in oesophageal adenocarcinoma. [32] [33] [34] ER-expressing breast tumours seem to have a better prognosis if they also express the anti-apoptotic protein, bcl-2. 35, 36 Likewise, a loss of bcl-2 expression in oesophageal adenocarcinoma may lead to tumour progres- Fig. 1a -Forest plot showing odds ratios (ORs) and associated 95% confidence interval (95% CI) for the risk of oesophageal and gastric junction adenocarcinoma associated with ever/never breastfeeding among parous women. Estimates from logistic regression in individual studies and pooled analysis (total). Data from Australian, Irish and United Kingdom (UK) studies.
sion and poorer survival. 37 Oxytocin, a hormone associated with breastfeeding, can regulate tumour growth via activation of the oxytocin receptor. Both oxytocin and its receptor have shown expression throughout the gastrointestinal tract, although their functions in the tract are not known. 38 The relatively transient depletion of oestrogen and progesterone 39 and high levels of prolactin and oxytocin 26 during breastfeeding are unlikely to have a direct impact on oesophageal and gastric junction adenocarcinoma development later in life. However, lactation may cause long-term modification of endogenous hormones or their receptors; increasing prolactin and oxytocin and decreasing a woman's cumulative exposure to oestrogen, and in this way decreasing the risk of oesophageal and gastric junction adenocarcinoma. The androgen receptor has also been shown to be expressed on oesophageal adenocarcinoma cells, however, its impact on oesophageal adenocarcinoma aetiology and prognosis is not clear. 40 The role of parity has been investigated in upper gastrointestinal cancers with inconsistent findings. [41] [42] [43] The only previous study on parity and oesophageal and gastric junction adenocarcinoma reported no association. 16 The suggestions of an inverse association between increasing parity and risk of oesophageal and gastric junction adenocarcinoma in the current study seem uncertain since the results were not statistically significant. Like the breastfeeding finding, our finding of a decreased risk of oesophageal and gastric junction adenocarcinoma associated with increased parity may be somewhat reflective of the decreased risk of breast, ovarian and endometrial cancers associated with multiparity. [44] [45] [46] Age at first birth, another important risk factor for breast cancer, was only available for one study, and so we were unable to assess the effect of this variable on oesophageal and gastric junction adenocarcinoma risk with any precision. It is difficult to draw conclusions from our parity findings, however, as we found no association between ever being pregnant and oesophageal and gastric junction adenocarcinoma. In the only previous study of the role of hormone replacement therapy and oesophageal and gastric junction adenocarcinoma aetiology, based on prescription data, no protective effect was found 10 (OR = 1.17, 95% CI = 0. 41-3.32) . A lack of association with oesophageal and gastric junction adenocarcinoma was also reported in a cohort study of prostate cancer patients who used oestrogen therapy suggesting no role of exogenous female hormones on oesophageal and gastric junction adenocarcinoma aetiology among men. 7 Our findings may indicate a reduced risk of oesophageal and gastric junction adenocarcinoma associated with the use of hormone replacement therapy, but this was not evident when we restricted our analysis to oesophageal adenocarcinoma cases only. Approximately 1-2% of the population have Barrett's metaplasia, 56 a precursor lesion to oesophageal and gastric junction adenocarcinoma. The incidence rate of oesophageal and gastric junction adenocarcinoma among individuals with Barrett's is approximately 6-7 per 1000-person years. 56 To the best of our knowledge, however, there are as yet no published studies investigating the association of reproductive and sex hormonal factors with the risk of Barrett's metaplasia or progression to adenocarcinoma in patients with Barrett's metaplasia. This warrants investigations, since any potential association could have major implications for our understanding of oesophageal carcinogenesis and prevention. The present study has strengths and limitations. A major strength is the availability of individual-level data for the pooled analyses, which are not available in meta-analyses of published data. Through the pooling of four populationbased datasets, this is the largest study to date to investigate the impact of reproductive factors on oesophageal and gastric junction adenocarcinoma risk in women. Yet, for at least some of the reproductive variables, our study had limited statistical power, partly because data were not collected on all exposures of interest in each study. Moreover, information on these variables was collected by slightly different questions (see Appendix), thus increasing the risk of misclassification.
Women included in the current study were mostly Caucasian, so our findings may not be generalisable to patients of other ethnicity. However, oesophageal and gastric junction adenocarcinoma has the highest incidence rate among Caucasians. We had no information on the type of hormone replacement therapy or on the use of injected contraceptives, which may have impacted on oesophageal and gastric junction adenocarcinoma risk, although the frequency of the latter is likely to be low among women of the age of those in the current studies. While we analysed age when menstrual periods stopped, we could not distinguish between natural menopause, hysterectomy or women who went straight onto hormone replacement therapy and whose periods continued. We were unable to adjust for dietary factors, 47, 48 H. pylori infection or medications such as NSAIDs, since these data were not available from all of the studies. The timing of BMI measurement was not uniform for the four studies. However, a pattern of higher BMI among cases than controls was seen in each of the included studies. Moreover, we adjusted our analyses for the study to account for such differences in data coding and categorisation. The higher frequency of reflux and higher BMI among women with oesophageal and gastric junction adenocarcinoma compared with controls concur with the published research, thus lending validity to our data. 11, [49] [50] [51] [52] Case-control studies may be subject to recall bias.
It seems likely, however, that recall of the number of children, pregnancies, use of hormone replacement therapy or oral contraceptives and history of breastfeeding is quite accurate. 53 It is unlikely that the recall of these factors differs substantially between cases and controls as they are not known to be associated with this cancer. Our study may be prone to selection bias. Some of the included studies report low response rates among controls 21 -65%, 48% and 42% in the UK, Australian and Irish studies, respectively. There was no evidence of a sex-related difference in response rates for the Australian study; this information was not available for the Irish study. Individuals who participated as controls may have been more health conscious than cases, which may be particularly relevant to the observed reduced risk of oesophageal and gastric junction adenocarcinoma among individuals who breastfed. Compared with women who did not breastfeed, those who breastfed had longer years of education, were more frequently alcohol drinkers, had lower BMI, lower prevalence of a history of reflux and were less frequently smokers. We observed a relatively high rate of breastfeeding among women included in the current study, particularly among controls (Australian study 82% controls versus 78% cases; Irish study 58% controls versus 38% cases, UK study 76% controls versus 53% cases). This compares to approximately 60% of women in the UK Million Women's Study 54 and 86% of women in Australia in 1995 (rates from earlier years were not available). 55 In summary, through pooling of four population-based case-control studies, we were able to investigate the impact of reproductive variables on oesophageal and gastric junction adenocarcinoma incidence in women. The findings suggest an inverse association between breastfeeding and risk of oesophageal and gastric junction adenocarcinoma. The underlying biological mechanism(s) remains to be elucidated. Most studied reproductive and sex hormonal factors did not seem to be associated with oesophageal and gastric junction adenocarcinoma, but the uncertainty about some of these factors, particularly a possible decreased risk of oesophageal and gastric junction adenocarcinoma with increased parity and use of hormone replacement therapy, supports the need to further evaluate these factors in prospective studies.
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